Drugs / BAY3630942
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06345001 | Aug 2024 → Mar 2025 | hepatocellular carcinoma | Bayer | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY3630942 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06345001 ↗ |
| Modality | Monoclonal antibody | “BAY 3630942, a 89Zr-labeled Monoclonal Antibody” NCT06345001 ↗ |
| Route | Intravenous | “IV, Single administration” NCT06345001 ↗ |